BioPharmSignal logoBioPharmSignal

Biotech News

Adlai Nortye to Participate in Upcoming Investor Conferences

Adlai Nortye Ltd. (ANL)Adlai Nortye Ltd.Company update

SINGAPORE and NORTH BRUNSWICK, N.J., March 3, 2026 – Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that members of its management team are scheduled to participate

Related news

ANLAdlai Nortye Ltd.2026-08-03 11:00 EST

Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia

ANLAdlai Nortye Ltd.2026-07-16 11:00 EST

Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025

MMSIMerit Medical2026-08-05 16:00 EST

Merit Medical to Participate in Upcoming Investors Conferences in August

HRMYHarmony Biosciences2026-08-06 12:05 EST

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

IMTXImmatics2026-07-17 14:25 EST

Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026

GERNGeron2026-06-01 12:00 EST

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

View all latest news

Adlai Nortye Ltd.

Annovis Bio is a biotechnology company focused on neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Its story centers on trying to address difficult CNS diseases with a focused molecular approach.

Recent company news

ANLAdlai Nortye Ltd.2026-08-03 11:00 EST

Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia

ANLAdlai Nortye Ltd.2026-07-16 11:00 EST

Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025

ANLAdlai Nortye Ltd.2026-07-13 11:00 EST

Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists

ANLAdlai Nortye Ltd.2026-04-16 10:59 EST

Adlai Nortye Announces $150.0 Million Private Placement Equity Financing

ANLAdlai Nortye Ltd.2026-03-03 07:00 EST

Adlai Nortye to Participate in Upcoming Investor Conferences

Stock data

Close
13.84 USD
Market cap
745.73M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States